?> Youth tobacco product use, including e-cigarettes, drops during 2015-2016 - DirectorsTalk

Youth tobacco product use, including e-cigarettes, drops during 2015-2016

But 3.9 million youth were still using tobacco products in 2016.

The number of middle and high school students who say they are current tobacco users – defined as having used a tobacco product in the past 30 days – dropped from 4.7 million in 2015 to 3.9 million in 2016, according to new data published by the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products. These findings from the 2016 National Youth Tobacco Survey appear in CDC’s Morbidity and Mortality Weekly Report.

The decline in use of tobacco products was primarily driven by a drop in e-cigarette use among middle and high school students from 3 million in 2015 to just under 2.2 million in 2016. In addition, declines were also seen during 2015-2016 among high school students who used two or more tobacco products, any combustible tobacco products, and hookah.

Far too many young people are still using tobacco products, so we must continue to prioritize proven strategies to protect our youth from this preventable health risk, said CDC Acting Director Anne Schuchat, M.D.

 

Tobacco prevention and control strategies at the national, state, and local levels likely contributed to the reduction in tobacco use, particularly for e-cigarettes. However, the report notes that continued surveillance of all forms of youth tobacco product use is important to help determine whether the current downward trend in youth tobacco use continues.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Oncimmune Holdings PLC

    More articles like this

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous

    Oncimmune signs go-to-market partnership with Synexa Life Sciences

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker

    Oncimmune signs new commercial contract with Verily Life Sciences 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company (parent company to Google), focusing on the autoantibody profiling of patients

    Oncimmune Holdings Notice of half year results

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022. ImmunoINSIGHTS Service Business Oncimmune

    Oncimmune achieves FY2021 revenue of £3.7 million

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its audited results for the year ended 31 May 2021 and provides an update on recent progress and the outlook for the current financial year.

    Oncimmune to evaluate the profile of patients using ImmunoINSIGHTS

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The